The Role of Pretreatment Serum Interleukin 6 in Predicting Short-Term Mortality in Patients with Advanced Pancreatic...

Area of Science:

• Oncology
• Immunology
• Biomarker Discovery

Background:

• Pancreatic ductal adenocarcinoma (PDAC) presents aggressive progression and poor survival rates.
• Elevated interleukin 6 (IL-6) is observed in PDAC patients, suggesting a role in disease severity.

Purpose of the Study:

• To evaluate elevated IL-6 levels as a prognostic biomarker in advanced PDAC.
• To determine the correlation between IL-6 levels and patient survival outcomes.

Main Methods:

• Serum samples from 77 advanced PDAC patients were analyzed using ELISA.
• Receiver operating characteristic (ROC) curve analysis determined optimal cutoff values for IL-6 and the IL-6:sIL-6Rα ratio.
• Patients were stratified into low and high IL-6 groups to compare survival.

Main Results:

• High IL-6 levels were associated with adverse prognostic features, including poor differentiation, higher tumor burden, and low albumin.
• Patients with lower IL-6 levels demonstrated significantly better median overall survival and progression-free survival.
• Multivariate analysis identified IL-6 levels as an independent predictor of worse outcomes in advanced PDAC.

Conclusions:

• Interleukin 6 (IL-6) serves as a critical prognostic biomarker for advanced pancreatic ductal adenocarcinoma (PDAC).
• IL-6 levels can aid in predicting disease progression and tailoring treatment strategies.
• Further research into IL-6's role in systemic inflammation and the tumor microenvironment is warranted.